Intravesical Activation of the Cation Channel TRPV4 Improves Bladder Function in a Rat Model for Detrusor Underactivity

被引:41
作者
Deruyver, Yves [1 ,2 ,3 ]
Weyne, Emmanuel [1 ]
Dewulf, Karel [1 ]
Rietjens, Roma [1 ,2 ,3 ]
Pinto, Silvia [2 ,3 ,4 ]
Van Ranst, Nele [2 ,3 ,4 ]
Franken, Jan [1 ,2 ,3 ]
Vanneste, Matthias [1 ,2 ,3 ,4 ]
Albersen, Maarten [1 ]
Gevaert, Thomas [1 ,5 ]
Vennekens, Rudi [2 ,3 ,4 ]
De Ridder, Dirk [1 ,3 ]
Voets, Thomas [2 ,3 ,4 ]
Everaerts, Wouter [1 ,2 ,3 ]
机构
[1] Katholieke Univ Leuven, Dept Dev & Regenerat, Lab Expt Urol, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Cellular & Mol Med, Lab Ion Channel Res, Leuven, Belgium
[3] Katholieke Univ Leuven, TRP Channel Res Platform Leuven TRPLe, Leuven, Belgium
[4] VIB Ctr Brain & Dis Res, Leuven, Belgium
[5] Katholieke Univ Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, Leuven, Belgium
关键词
Bladder afferent signalling; Pelvic nerve injury; Transgenic rats; Transient receptor potential channels; Transient receptor potential; vanilloid 4 (TRPV4); Underactive bladder; Voiding dysfunction; TRPV4 knockout rats; RECEPTOR POTENTIAL VANILLOID-4; URETHRAL SPHINCTER FUNCTION; DYSFUNCTION; ULTRASOUND; FREQUENCY; CAPACITY;
D O I
10.1016/j.eururo.2018.05.020
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Improvement of bladder emptying by modulating afferent nerve activity is an attractive therapeutic strategy for detrusor underactivity. Transient receptor potential vanilloid 4 (TRPV4) is a sensory ion channel in urothelial cells that contribute to the detection of bladder filling. Objective: To investigate the potential benefit of intravesical TRPV4 agonists in a pelvic nerve injury rat model for detrusor underactivity. Design, setting, and participants: Female wild-type and Trpv4 knockout rats underwent sham surgery or bilateral pelvic nerve injury (bPNI). Four weeks later, rats underwent cystometry with infusion of the TRPV4 agonist GSK1016790A. Bladders were harvested for in vitro pharmacological studies, quantitative reverse polymerase chain reaction and immunohistochemistry. Outcome measurements and statistical analysis: Data are expressed as median +/- interquartile range. Statistical comparisons were made using the Mann-Witney U test and Wilcoxon signed rank test as appropriate. Results and limitations: Rats with bPNI showed a phenotype characteristic of detrusor underactivity with lower-amplitude voiding contractions, decreased voiding frequency, and increased postvoid residual. Intravesical application of GSK1016790A increased voiding frequency and reduced postvoid residual in wild-type, but not Trpv4(-/-), rats. In isolated bladder strips, GSK1016790A did not induce relevant contractions, indicating that the observed improvements in bladder function are the result of increased afferent signalling through TRPV4 activation, rather than a local effect on the detrusor. The altered urinary phenotype of Trpv4(-/-) mice was not apparent in the Trpv4(-/-) rat model, suggesting species-related functional variations. Our results are limited to the preclinical setting in rodents. Conclusions: Intravesical activation of TRPV4 improves bladder dysfunction after bPNI by increasing afferent signalling. Patient summary: We demonstrate that the sensory protein transient receptor potential vanilloid 4 (TRPV4) can be targeted to improve bladder function in animals that have iatrogenic injury to the nerves innervating the bladder. Further research is required to determine whether these results can be translated to patients with an underactive bladder. (C) 2018 The Author(s). Published by Elsevier B.V.
引用
收藏
页码:336 / 345
页数:10
相关论文
共 25 条
[21]   N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity:: Part I [J].
Thorneloe, Kevin S. ;
Sulpizio, Anthony C. ;
Lin, Zuojun ;
Figueroa, David J. ;
Clouse, Angela K. ;
McCafferty, Gerald P. ;
Chendrimada, Tim P. ;
Lashinger, Erin S. R. ;
Gordon, Earl ;
Evans, Louise ;
Misajet, Blake A. ;
DeMarini, Douglas J. ;
Nation, Josephine H. ;
Casillas, Linda N. ;
Marquis, Robert W. ;
Votta, Bartholomew J. ;
Sheardown, Steven A. ;
Xu, Xiaoping ;
Brooks, David P. ;
Laping, Nicholas J. ;
Westfall, Timothy D. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 326 (02) :432-442
[22]   Pathophysiology and animal modeling of underactive bladder [J].
Tyagi, Pradeep ;
Smith, Phillip P. ;
Kuchel, George A. ;
de Groat, William C. ;
Birder, Lori A. ;
Chermansky, Christopher J. ;
Adam, Rosalyn M. ;
Tse, Vincent ;
Chancellor, Michael B. ;
Yoshimura, Naoki .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 :S11-S21
[23]   Chronic Administration of Anticholinergics in Rats Induces a Shift from Muscarinic to Purinergic Transmission in the Bladder Wall [J].
Uvin, Pieter ;
Boudes, Mathieu ;
Menigoz, Aurelie ;
Franken, Jan ;
Pinto, Silvia ;
Gevaert, Thomas ;
Verplaetse, Ruth ;
Tytgat, Jan ;
Vennekens, Rudi ;
Voets, Thomas ;
De Ridder, Dirk .
EUROPEAN UROLOGY, 2013, 64 (03) :502-510
[24]   The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation [J].
Uvin, Pieter ;
Everaerts, Wouter ;
Pinto, Silvia ;
Alpizar, Yeranddy A. ;
Boudes, Mathieu ;
Gevaert, Thomas ;
Voets, Thomas ;
Nilius, Bernd ;
Talavera, Karel ;
De Ridder, Dirk .
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2012, (66)
[25]   Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2 [J].
Willette, Robert N. ;
Bao, Weike ;
Nerurkar, Sandhya ;
Yue, Tian-li ;
Doe, Chris P. ;
Stankus, Gerald ;
Turner, Gregory H. ;
Ju, Haisong ;
Thomas, Heath ;
Fishman, Cindy E. ;
Sulpizio, Anthony ;
Behm, David J. ;
Hoffman, Sandra ;
Lin, Zuojun ;
Lozinskaya, Irina ;
Casillas, Linda N. ;
Lin, Min ;
Trout, Robert E. Lee ;
Votta, Bartholomew J. ;
Thorneloe, Kevin ;
Lashinger, Erin S. R. ;
Figueroa, David J. ;
Marquis, Robert ;
Xu, Xiaoping .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 326 (02) :443-452